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Abstract
Purpose TNM classification of solitary internal mammary
lymph node metastases (IMLNMs) in breast cancer varies
depending on their method of detection: sentinel lymph
node biopsy (pN1b) or clinical examination including
radiological and/or physical examination (pN2b). This
study aimed to evaluate whether there is a difference in
prognosis between both groups.
Methods Data of all patients diagnosed with primary
invasive epithelial breast cancer between 2005 and 2008
were obtained from the Netherlands Cancer Registry.
Patients with IMLNMs were divided in groups according to
their pN1b and pN2b status. The main outcome measures
disease-free survival (DFS) after 5 years and overall sur-
vival (OS) after 8 years were analyzed using Kaplan–Meier
survival analysis. Cox regression analysis was used to
determine independent predictors for DFS and OS.
Results A total of 73 patients with pN1b status and 28
patients with pN2b status were included. DFS rate was
74.1% in the pN1b group compared to 85.0% in the pN2b
group (p = 0.211). Regarding OS, 20.5% (pN1b) and
25.0% (pN2b) of the patients deceased within 8 years of
follow-up (p = 0.589). In multivariable cox regression
analysis, nodal status was not statistically significant for
DFS (HR 0.29 [95% CI 0.04–2.33], p = 0.244) or OS (HR
1.04 [95% CI 0.37–2.89], p = 0.947).
Conclusions Although the TNM classification considers
pN1b and pN2b to be distinct prognostic entities, we did
not observe any prognostic differences between these
groups. Therefore, solitary IMLNMs may be regarded as a
single category in the future and revision of TNM classi-
fication should be considered.
Keywords Breast cancer  Internal mammary lymph
node  Neoplasm staging  Prognosis
Introduction
In breast cancer staging, TNM classification is used to
determine the anatomic extent of the disease and conse-
quently identify specific subgroups with different prog-
noses [1, 2]. Pathologic nodal staging is an important
element in this classification as the presence of regional
nodal metastases is associated with impaired survival [3].
These metastases can occur not only in axillary but also in
extra-axillary lymph nodes, such as intramammary, peri-
clavicular, interpectoral, and internal mammary lymph
nodes.
Pathological nodal staging of internal mammary lymph
node metastases (IMLNMs) has changed over time. In the
fourth (1987) and fifth edition (1997) edition of TNM
classification, all IMLNMs were classified as pN3, because
by that time IMLNMs were considered of great importance
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in formulating the prognosis of patients [4, 5]. Since the
introduction of the sixth edition in 2002, IMLNMs are
divided into pN1b, pN1c, pN2b, or pN3b status depending
on their method of detection and possible concurrent
axillary lymph node metastases [6, 7]. IMLNMs may be
detected by physical and/or radiological examination or by
sentinel lymph node biopsy (SLNB) [8]. Nowadays, soli-
tary IMLNMs, in the absence of axillary lymph node
metastases, are considered pN1b when detected at SLNB
and pN2b when detected at clinical examination (including
physical and/or radiological examination) [7, 9, 10].
Dividing solitary IMLNMs based on the method of
detection, TNM implies a difference in prognosis between
both groups. Therefore, the aim of this study was to eval-
uate whether a true difference in prognosis exists between
pN1b and pN2b status.
Methods
Data collection
Data of all patients diagnosed between 2005 and 2008 with
primary invasive epithelial breast cancer were obtained
from the Netherlands Cancer Registry (NCR), which is
managed by the Netherlands Comprehensive Cancer
Organisation (IKNL). The NCR ensures a high-quality data
collection using specially trained employees who extract
patient, tumor, and treatment characteristics directly from
the patient records. Groups were defined according to pN1b
(IMLNMs detected at SLNB) and pN2b (IMLNMs detec-
ted at clinical examination) nodal status. Characteristics
collected were age, tumor characteristics (size, location,
stage, grade, subtype, and receptor status), and treatment
characteristics (adjuvant chemotherapy, targeted therapy,
endocrine therapy, and radiation therapy).
Treatment
During the study period, the Dutch national guideline of
2005 was in use [11]. This guideline recommended regio-
nal treatment depending on nodal status: SLNB was indi-
cated in clinically node-negative patients, based on
physical examination, with axillary ultrasound being
commonly used but not mandatory at that time. Clinically
node-positive (N?) patients, patients with positive SLNB,
or patients with a contraindication for SLNB underwent
axillary lymph node dissection (ALND).
In all patients who underwent lumpectomy, whole-
breast irradiation was indicated. After mastectomy, chest
wall irradiation was indicated in the case of irradical
resection, pT4 tumors, and involvement of the pectoral
muscle or skin. For pT3 tumors, chest wall irradiation was
considered individually. Irradiation of regional nodal fields
was included in case of four or more axillary lymph node
metastases or involvement of top axillary lymph nodes
after ALND. The recommended dose was 45–50 Gy in
5 weeks, with a boost to 60–70 Gy when residual tumor
was present.
Chemotherapy was recommended in all premenopausal
N? women and in postmenopausal N? women aged 50–69
with estrogen receptor (ER)- and progesterone receptor
(PR)-negative tumors. Furthermore, chemotherapy was
considered in physically fit postmenopausal N? women
aged 50–59 with ER- and PR-positive tumors and in N?
women aged 60–69 if four or more regional lymph nodes
were involved. Chemotherapy regimen consisted of five
courses of 5-Fluorouracil, Epirubicin, Cyclophosphamide
(FEC) or six courses of Taxotere, Adriamycin, and
Cyclophosphamide (TAC). Targeted therapy (trastuzumab)
was recommended in selected cases in addition to
chemotherapy in case of human epidermal growth factor 2
receptor amplification (HER2?). Endocrine therapy was
recommended for all ER- and/or PR-positive tumors.
Statistical analysis
All analyses were performed using IBM SPSS Statistics
version 23.0 (IBM Corporation, Armonk, New York, USA)
and p values \0.05 were considered statistically signifi-
cant. Differences between pN1b and pN2b groups with
regard to patient, tumor, and treatment characteristics were
tested using the Fisher’s Exact Test and Pearson Chi-square
test for categorical variables and Mann–Whitney U test for
continuous variables.
The main outcome measures were disease-free survival
(DFS) after 5 years and overall survival (OS) after 8 years.
DFS was defined as the absence of any first local, regional,
or contralateral recurrence, distant metastasis, or mortality
within 5 years. DFS rate included all patients without any
event, who visited the hospital in the fifth year after
diagnosis for regular check-up. OS was defined as the time
interval between date of diagnosis and date of death or date
of emigration, as obtained from the Municipal Personal
Records Database and completed until December 31, 2014.
Patients were censored at the date of their first event, date
of last follow-up, date of death, or date of emigration,
whatever came first. Patients without follow-up data were
excluded from DFS analysis. DFS and OS were analyzed
using Kaplan–Meier survival analysis and compared with
the log-rank test.
Univariable and multivariable Cox regression analyses
were used to determine relevant predictors for DFS and
OS. Outcome measure was hazard ratio (HR) with corre-
sponding 95% confidence intervals (CI). Due to the limited
number of events, multivariable cox regression could only
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be performed with a limited number of variables [12].
Nodal status together with the most significant variables in




Between 2005 and 2008, a total of 51,239 patients were
diagnosed with primary invasive epithelial breast cancer.
After selection for pN1b (n = 73, 72.3%) and pN2b
(n = 28, 27.7%) status, a total of 101 patients remained,
comprising 0.2% of the total population (Fig. 1). In com-
parison to pN1b status, pN2b was associated with lower
rates of pT0-1 stage carcinoma (32 vs 59%, p = 0.016),
lower rates of grade 1–2 carcinoma (32 vs 63%,
p = 0.005), and larger mean tumor size (28 vs 20 mm,
p = 0.008). A detailed overview of baseline patient, tumor,
and treatment characteristics is shown in Table 1.
Disease-free survival (DFS)
Five-year follow-up data were complete for 54 patients
(74.0%) in the pN1b group and 20 patients (71.4%) in the
pN2b group. An event occurred in 13 patients (24.1%) in
the pN1b group compared to two patients (10.0%) in the
pN2b group (p = 0.211) (Fig. 2a). DFS rate was 74.1% in
the pN1b group and 85.0% in the pN2b group.
When taking the effect of endocrine therapy and triple-
negative subtype into account in multivariable Cox
regression analysis, pN2b status was not significantly dif-
ferent compared to pN1b status (HR 0.29 [95% CI
0.04–2.33], p = 0.244). Neither endocrine therapy nor
triple-negative subtype was identified as an independent
predictor for improved DFS (HR 0.46 [95% CI 0.12–1.86],
p = 0.277 and HR 1.56 [95% CI 0.35–7.06], p = 0.561,
respectively) (Table 2).
Overall survival (OS)
Median follow-up time of patients was 7.7 years (range
59 days–9.9 years). After 8 years of follow-up, 15 patients
(20.5%) in the pN1b group and seven patients (25.0%) in
the pN2b group were deceased (p = 0.589) (Fig. 2b).
When taking the effect of tumor size (per mm incre-
ment), endocrine therapy, and trastuzumab into account in
multivariable Cox regression analysis, pN2b status still was
not significantly different compared to pN1b status (HR
1.04 [95% CI 0.37–2.89], p = 0.947). Tumor size (HR
1.02 [95% CI 1.00–1.05], p = 0.117), endocrine therapy
(HR 0.40 [95% CI 0.15–1.04], p = 0.060), and trastuzu-
mab (HR 0.26 [95% CI 0.04–1.98], p = 0.192) did not
have a statistically significant influence on OS (Table 3).
Discussion
According to the current TNM classification, patients with
solitary IMLNMs are considered pN1b when detected
during SLNB and pN2b when observed during clinical
examination (including radiologic and/or physical exami-
nation), suggesting a prognostic difference between these
two groups [1, 2, 6]. However, our study demonstrated that
both DFS after 5 years (p = 0.211) and OS after 8 years
(p = 0.589) were not significantly different between both
groups. Consequently, it is questionable whether the cur-
rent TNM classification of IMLNMs is still appropriate.
The comparable prognosis of the pN1b and pN2b group
in our study can be explained by the great improvements in
imaging modalities over the last decade. In the past, clin-
ical detection of IMLNMs was mostly restricted to large
internal mammary lymph nodes found during physical
examination (and later additional ultrasound if indicated).
Consequently, IMLNMs detected during physical exami-
nation were much larger and thus associated with worse
prognosis than IMLNMs detected during SLNB. In distant
past, 10-year overall survival ranged from 0 to 61% in
patients with IMLNMs compared to our cohort of patients
with SLNB-detected IMLNMs, of which only 20.5% of the
patients deceased after 8 years of follow-up [6, 13, 14].
Possible explanations for improved overall survival can be
the introduction of other systemic regimen, such as tras-
tuzumab, or detecting smaller IMLNMs with SLNB.
Fig. 1 Flowchart of patient selection. nos indicates not otherwise
specified, mi indicates micrometastases, pN3 includes pN3a, pN3b,
and pN3c
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Fig. 2 Kaplan–Meier survival curves of disease-free survival (a) and overall survival (b)
Table 1 Patient demographics
and characteristics of tumor and
treatment subdivided according
to pN1b and pN2b status
pN1b (n = 73) pN2b (n = 28) p value
Mean age, years (SD) 55 (14) 58 (17) 0.693
Mean tumor size, mm (SD) 20 (11) 28 (15) 0.008
pT-stage, n (%)
T0–1 43 (59) 9 (39) 0.016
T2–4 30 (41) 14 (61) 0.419
Unknown – 5 –
Tumor type, n (%)
Ductal 54 (74) 19 (68) 0.539
Lobular 7 (10) 4 (14) 0.492
Mixed ductal & lobular 4 (5) 3 (11) 0.393
Other 8 (11) 2 (7) 0.722
Grade, n (%)
1–2 46 (67) 9 (38) 0.005
3 23 (33) 15 (62) 0.040
Unknown 4 4 –
Receptor status, n (%)
ER?, PR?, HER2- 39 (56) 16 (63) 0.737
ER?, PR-, HER2- 8 (11) 3 (11) 1.000
ER?, HER2? 9 (13) 3 (11) 1.000
ER-, HER2? 3 (4) 3 (11) 0.344
Triple negative 11 (16) 1 (4) 0.171
Unknown 3 2 –
Chemotherapy, n (%) 44 (60) 17 (61) 0.968
Radiation therapy, n (%) 55 (75) 19 (68) 0.447
Trastuzumab, n (%) 13 (18) 3 (11) 0.546
Endocrine therapy, n (%) 51 (70) 19 (68) 0.845
SD standard deviation, pT-stage pathologic tumor stage, ER estrogen receptor, PR progesterone receptor,
HER2 human epidermal growth factor receptor 2
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Nowadays, the size of internal mammary lymph nodes
detected using state-of-the-art imaging techniques such as
PET/CT and MRI approaches the size of internal mammary
nodes visualized during SLNB [15–17]. This suggests
comparable prognosis of SLNB-detected IMLNMs and
imaging-detected IMLNMs.
Routine evaluation of IMLNMs is controversial and is
currently not recommended. The overriding arguments




Univariable Cox regression Multivariable Cox regression
HR [95% CI] p value HR [95% CI] p value
pN1b Reference Reference
pN2b 0.40 [0.09–1.77] 0.227 0.29 [0.04–2.33] 0.244
Tumor size (per mm increment) 1.04 [1.00–1.07] 0.051
pT-stage
T2–4 versus T0–1 1.96 [0.71–5.42] 0.194
Tumor grade
3 versus 1–2 1.07 [0.37–3.09] 0.897
Triple-negative subtype
Yes versus no 3.58 [1.10–11.63] 0.034 1.56 [0.35–7.06] 0.561
Radiation therapy
Yes versus no 1.13 [0.36–3.54] 0.838
Chemotherapy
Yes versus no 1.21 [0.44–3.35] 0.709
Endocrine therapy
Yes versus no 0.25 [0.09–0.70] 0.008 0.46 [0.12–1.86] 0.277
Trastuzumab
Yes versus No 0.33 [0.04–2.47] 0.200
HR hazard ratio, CI confidence interval, pT-stage pathological tumor stage
Table 3 Univariable and
multivariable Cox regression
analysis for overall survival
Univariable Cox regression Multivariable Cox regression
HR [95% CI] p value HR [95% CI] p value
pN1b Reference 0.590 Reference 0.947
pN2b 1.28 [0.52–3.14] 1.04 [0.37–2.89]
Tumor size (per mm increment) 1.04 [1.01–1.06] 0.003 1.02 [1.00–1.05] 0.117
pT-stagea
T2–4 versus T0–1 2.19 [0.91–5.29] 0.082
Tumor grade
3 versus 1–2 1.73 [0.67–4.49] 0.259
Triple-negative subtype
Yes versus no 2.22 [0.74–6.71] 0.156
Radiation therapy
Yes versus no 0.85 [0.31–2.30] 0.748
Chemotherapy
Yes versus no 1.06 [0.45–2.48] 0.897
Endocrine therapy
Yes versus no 0.30 [0.13–0.69] 0.005 0.40 [0.15–1.04] 0.060
Trastuzumab
Yes versus no 0.22 [0.03–1.63] 0.138 0.26 [0.04–1.98] 0.192
HR hazard ratio, CI confidence interval, pT-stage pathological tumor stage
a Excluded from multivariable analysis due to collinearity with tumor size
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against routine evaluation of IMLNMs include their low
incidence, their very limited impact on prognosis and
treatment strategy, and the fact that tissue sampling is
rather complex and associated with a risk of morbidity
[13, 18, 19]. However, detection of IMLNMs during radi-
ological examinations and SLNB will continue to occur
and possibly even increase with improving accuracy of
these techniques. Their unambiguous and accurate classi-
fication will remain important as the detection of IMLNMs
may alter nonsurgical treatment in patients [20]. Current
guidelines advise internal mammary irradiation in all
patients with histologically proven and/or PET-positive
IMLNMs and in patients with N2 status additional radio-
therapy of the periclavicular region and/or thoracic wall
can be advised [9, 10, 21]. A previous study by Heuts et al.
demonstrated that adjuvant treatment plans were changed
in only 3.4% (27/789) of the patients based on the presence
of IMLNMs [20]. If TNM classification would be adapted
by including all isolated IMLNMs in one group, then
additional radiation therapy, besides internal mammary
irradiation, could be omitted in these patients.
A major strength of this retrospective study is the use of
a large population-based dataset from the Netherlands
Cancer Registry providing patient, tumor, and treatment
characteristics. However, as metastatic spread to the
internal mammary lymph node chain is rare, a limited
number of patients were only available per subgroup [22].
Early surgical series showed internal mammary involve-
ment in 9.1% of patients undergoing extended radical
mastectomy [23]. According to our study, solitary
IMLNMs were reported in only 0.2% of the population
suggesting that IMLNMs may currently be underdiag-
nosed. Firstly, routine evaluation of IMLNMs is not rec-
ommended. Secondly, according to literature, superficial
tracer injection (intradermal or periareaolar) often used
during SLNB yields a lower visualization rate of internal
mammary sentinel lymph nodes compared to intra-
parenchymal tracer injection (peritumoral, intratumoral, or
subtumoral) [24]. All in all, the results of this study should
be interpreted in the context of this small study population.
Furthermore, the staging technique used to classify
patients as pN2b in our cohort was unknown. As a con-
sequence, there was no distinction in our cohort of pN2b
patients detected by for instance physical examination,
ultrasound, MRI, or PET-CT. Yet, a previous study of
Jochelson et al. demonstrated a difference in the prevalence
between several imaging techniques for detecting internal
mammary adenopathy [17].
Another study limitation may be the completeness of
data. Nodal status was missing in over 4000 patients
(10.3%) of the overall population of patients diagnosed
with breast cancer in the Netherlands between 2005 and
2008. However, subclassification of pN1 (into pNmi, pN1a,
pN1b, and pN1c) and pN2 (into pN2a and pN2b) status
seems to be accurately registered as in the pN1 group only
seven patients were classified as pN1 not otherwise spec-
ified and none in the pN2 group (Fig. 1). Therefore, reg-
istration of nodal status in our cohort was performed
adequately.
In conclusion, our study did not observe any difference
in prognosis between pN1b and pN2b in terms of DFS and
OS. Since coincidental detection of IMLNMs during SLNB
and radiological examinations will continue to occur and
possibly even increase with improving accuracy of these
techniques, their unambiguous and accurate classification
will remain important. Therefore, more research on pN1b
and pN2b is advised and revision of TNM classification is
desirable as solitary IMLNMs may be regarded as a single
category.
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